A Phase 4 interventional study of Levetiracetam (Keppra) in Epilepsy, sponsored by UCB Pharma. Completed. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-11-15.
Sponsored by UCB Pharma · Phase 4, Interventional, and Treatment
Patients in community-based practices correspond to the 25% of patients who need a first add-on drug when not controlled by their standard monotherapy drug. This was a therapeutic use trial in which the population corresponds more closely to that seen in daily clinical practice.
1,805 studies on the registry are indexed under Epilepsy; 417 are open to participants now.
This study's enrollment of 35 is below the median of 50 across 1,206 interventional studies indexed under Epilepsy.
Browse Epilepsy studies →UCB Pharma is the lead sponsor of 238 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Safety and the tolerability of Keppra in a broad population of patients.
Obtain further information about optimal daily dose.
No study locations are listed for this record.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UCB Pharma